Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis [Phase 1]
Phase 1 safety and tolerability study of ABBV-744 alone or in combination with oral ruxolitinib or navitoclax in adult patients with myelofi…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions [Phase 3]
This Phase 3 trial compares luspatercept against placebo in patients with myeloproliferative neoplasm-associated myelofibrosis who are on JA…
-
CLINICAL_TRIALS other · 2025-07-03Clinical Trial Update: Connect® Myeloid Disease Registry
The Connect Myeloid Disease Registry sponsored by Celgene has been terminated. The registry involved conditions including primary myelofibro…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis [Phase 1]
Phase 1 clinical trial investigating a regimen of combination chemotherapy, total body irradiation, and donor blood stem cell transplant for…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis [Phase 2]
A Phase 2 clinical trial evaluating a combination of Ropeginterferon alfa-2b and ruxolitinib for myelofibrosis is currently recruiting, incl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants [Phase 2]
Phase 2 clinical trial update describing the addition of itacitinib to cyclophosphamide and tacrolimus for preventing graft-versus-host dise…
-
CLINICAL_TRIALS research · 2025-05-28Clinical Trial Update: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) [Phase 1]
An early-phase clinical trial evaluating Tagraxofusp as post-transplant maintenance in patients with CD123-positive acute myeloid leukemia, …
-
CLINICAL_TRIALS trial_result · 2025-05-25Clinical Trial Update: Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza [Phase 1]
Phase 1 blinded cross-over bioequivalence trial comparing Luitpold azacitidine with Vidaza has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis [Phase 2]
A Phase 2 trial comparing NS-018 to best available therapy in myelofibrosis was terminated, and results have been posted on May 23, 2025.
-
CLINICAL_TRIALS withdrawal · 2025-05-22Clinical Trial Update: A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis [Phase 2]
A Phase 2 trial evaluating INCB57643 in combination with ruxolitinib for myelofibrosis in JAK inhibitor-naïve patients has been withdrawn.
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History [NA]
This clinical trial update describes a study assessing the prevalence of germline gene mutations in patients with myeloproliferative neoplas…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: Haplo-HSCT for Myelofibrosis [NA]
A clinical trial investigating haploidentical hematopoietic stem cell transplantation for myelofibrosis is currently recruiting.
-
EMA approval · 2025-05-12EMA Authorised: Omjjara (Momelotinib dihydrochloride monohydrate) — GlaxoSmithKline Trading Services Limited
The European Medicines Agency authorized Omjjara (momelotinib dihydrochloride monohydrate) for myeloproliferative disorders including myelof…
-
FDA approval · 2025-05-12FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for INREBIC (fedratinib hydrochloride) submitted by Celgene Corporation.
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis [Phase 1]
A Phase 1 clinical trial is evaluating allogeneic hematopoietic cell transplantation with pegylated interferon alfa-2a for primary and secon…
-
CLINICAL_TRIALS trial_result · 2025-04-27Clinical Trial Update: RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 study evaluating everolimus (RAD001) in relapsed or refractory hematologic malignancies, including leukemia, mantle ce…
-
CLINICAL_TRIALS research · 2025-04-13Clinical Trial Update: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs [Phase 1]
A Phase 1 trial by Cellenkos evaluating a combination of T-regulatory cell therapy for myelofibrosis is currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis [Phase 2]
Phase II trial update for Flonoltinib maleate tablets in intermediate-high-risk myelofibrosis; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib
A completed trial update reports real-world patient-reported outcomes for fedratinib in myelofibrosis patients who progressed or were intole…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm [Phase 1]
Phase 1 clinical trial update for a CALR-mutant peptide vaccine in myeloproliferative neoplasms; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant [EARLY_Phase 1]
An early-phase 1 clinical trial is evaluating hyperbaric oxygen therapy in combination with allogeneic peripheral blood stem cell transplant…
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells
A recruiting study evaluating the effects of extracellular vesicles derived from mesenchymal stromal cells in patients with primary myelofib…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF [Phase 1, Phase 2]
This document reports the completion update of a Phase 1/2 trial evaluating the combination of ruxolitinib and pomalidomide in patients with…
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability [Phase 2]
Phase 2 clinical trial comparing ruxolitinib to allogeneic stem cell transplantation for myelofibrosis, with enrollment guided by donor avai…
-
CLINICAL_TRIALS other · 2025-03-30Clinical Trial Update: Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined [EARLY_Phase 1]
An early Phase 1 trial is planned to evaluate the combination of Tagraxofusp and Pacritinib in patients with intermediate-1 or higher myelof…